Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04830124 · ClinicalTrials.gov registry record · Phase 2
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
A Phase 2 study, sponsored by Mural Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT04830124 is a Phase 2 study that was terminated before completion, run by Mural Oncology. The registered enrollment target is 173 participants.
The verdict
NCT04830124, a Phase 2 study, was terminated before completion, sponsored by Mural Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
Interventions
- DRUG Pembrolizumab
- DRUG Nemvaleukin Alfa Subcutaneous
- DRUG Nemvaleukin Alfa Intravenous
- DRUG Nemvaleukin Alfa Intravenous Less Frequent Dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04830124
The ClinicalTrials.gov registry entry for NCT04830124 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mural Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04830124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04830124 about?
NCT04830124 is a clinical study titled "Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6". This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
What is the current status of trial NCT04830124?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2021-09-27. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT04830124?
The interventions under investigation include: Pembrolizumab (DRUG), Nemvaleukin Alfa Subcutaneous (DRUG), Nemvaleukin Alfa Intravenous (DRUG), Nemvaleukin Alfa Intravenous Less Frequent Dosing (DRUG).
Who is sponsoring clinical trial NCT04830124?
This trial is sponsored by Mural Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.